GSK, Kaleo Scale Back Orange Book IP In FTC Campaign - Law360

GSK, Kaleo Scale Back Orange Book IP In FTC Campaign – Law360

Source Node: 3032546
By Dani Kass (December 21, 2023, 10:54 PM EST) — The Federal Trade Commission’s push to stop drugmakers from artificially extending their exclusivity period by misusing a U.S. Food and Drug Administration database has resulted in GlaxoSmithKline, Kaleo and Impax Laboratories requesting nearly all questioned patents be delisted….

Time Stamp:

More from Law 360